Categories | Inventors

OCT Measurements of Retinal Vessel Relief Height in the Detection of Glaucoma

 

OHSU # 1930

Technology Overview:

Introduction

Retinal nerve fiber layer (NFL) and ganglion cell complex loss is used to help diagnose glaucoma and is particularly sensitive in advanced glaucoma.  However, OCT thickness measurements of the retinal NFL will vary significantly in the normal population.  Consequently, this measurement yields low sensitivity for the detection of early glaucoma.  This OCT software technology measures the vessel relief height, i.e. the height of the blood vessel relative to the NFL surface, to indicate nerve fiber loss that is not affected by inborn variation in the NFL thickness. By doing so, it enables a more reliable, quantifiable early glaucoma diagnosis test that is non-invasive in nature.

 

Patient Type

2010

2020

Glaucoma, U.S. only

2,222,000

3,333,000

U.S. Patients Undergoing Glaucoma Surgery / Year that will require OCT monitoring[1]

415,000

622,500

Ongoing Checkups in the US

10,474,000

11,584,000

TOTAL US MARKET PER YEAR

10,889,000

12,206,000

 

[1] This estimate assumes all individuals receiving glaucoma surgical procedures will need monitoring and thus the vessel height relief test.  It does not include individuals receiving glaucoma medications that do not undergo surgery.

 

Patients Suited for OCT Vessel Height Relief Measurement Test

The two broad patient populations most suited for the OCT Vessel Relief Height Measurement Test are:  1) undiagnosed, high risk individuals that require glaucoma diagnosis tests in periodic eye exams, and 2) individuals that require treatment monitoring, namely individuals diagnosed with early to moderate glaucoma.

 

Incidence of Glaucoma

According to one study, there will be 60.5 million people worldwide with glaucoma in 2010, increasing to 79.6 million by 2020. [1]  As to the US, another study indicates that “[m]ore than 2 million people in the United States have primary open-angle glaucoma [as of late 2009] and that number is expected to exceed 3 million by 2020.” [2] 

 

[1] Br J Ophthalmol 2006;90:262–267. doi: 10.1136/bjo.2005.081224

[2] Arch Ophthalmol. 2009;127[7]:900-905

 

 

Inventors:

Patents:

Patents Filed

Categories:

For more information, contact:

Arvin Paranjpe
Technology Development Manager
503-494-3210